|
1
|
Abramson DH, Shields CL, Munier FL and
Chantada GL: Treatment of retinoblastoma in 2015: Agreement and
disagreement. JAMA Ophthalmol. 133:1341–1347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Xue C, Cui H and Huang Z: High
expression of TAZ indicates a poor prognosis in retinoblastoma.
Diagn Pathol. 10:1872015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimaras H, Kimani K, Dimba EA, Gronsdahl
P, White A, Chan HS and Gallie BL: Retinoblastoma. Lancet.
379:1436–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chantada GL, Qaddoumi I, Canturk S, Khetan
V, Ma Z, Kimani K, Yeniad B, Sultan I, Sitorus RS, Tacyildiz N and
Abramson DH: Strategies to manage retinoblastoma in developing
countries. Pediatr Blood Cancer. 56:341–348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Canturk S, Qaddoumi I, Khetan V, Ma Z,
Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T,
Rodriguez-Galindo C, et al: Survival of retinoblastoma in
less-developed countries impact of socioeconomic and health-related
indicators. Br J Ophthalmol. 94:1432–1436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benavente CA and Dyer MA: Genetics and
epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang YQ, Li J and Yuan HF: Epidemiology
and risk factors of retinoblastoma in Chongqing area. Int J
Ophthalmol. 9:984–988. 2016.PubMed/NCBI
|
|
8
|
Finger PT, Harbour JW and Karcioglu ZA:
Risk factors for metastasis in retinoblastoma. Surv Ophthalmol.
47:1–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Wang X, Li Z, Liu H and Teng Y:
MicroRNA-183 suppresses retinoblastoma cell growth, invasion and
migration by targeting LRP6. FEBS J. 281:1355–1365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedman DL, Himelstein B, Shields CL,
Shields JA, Needle M, Miller D, Bunin GR and Meadows AT:
Chemoreduction and local ophthalmic therapy for intraocular
retinoblastoma. J Clin Oncol. 18:12–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shields CL and Shields JA: Retinoblastoma
management: Advances in enucleation, intravenous chemoreduction,
and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu CL, Tucker MA, Abramson DH, Furukawa K,
Seddon JM, Stovall M, Fraumeni JF Jr and Kleinerman RA:
Cause-specific mortality in long-term survivors of retinoblastoma.
J Natl Cancer Inst. 101:581–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sevignani C, Calin GA, Siracusa LD and
Croce CM: Mammalian microRNAs: A small world for fine-tuning gene
expression. Mamm Genome. 17:189–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Profumo V and Gandellini P: MicroRNAs:
Cobblestones on the road to cancer metastasis. Crit Rev Oncog.
18:341–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rottiers V, Najafi-Shoushtari SH, Kristo
F, Gurumurthy S, Zhong L, Li Y, Cohen DE, Gerszten RE, Bardeesy N,
Mostoslavsky R and Näär AM: MicroRNAs in metabolism and metabolic
diseases. Cold Spring Harb Symp Quant Biol. 76:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao C, Lu F and Chen H, Zhao F, Zhu Z,
Zhao X and Chen H: Clinical significance of circulating miRNA
detection in lung cancer. Med Oncol. 33:412016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Verma V and Lautenschlaeger T: MicroRNAs
in non-small cell lung cancer invasion and metastasis: From the
perspective of the radiation oncologist. Expert Rev Anticancer
Ther. 16:767–774. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li S, Gao M, Li Z, Song L, Gao X, Han J,
Wang F, Chen Y, Li W, Yang J and Han X: Role of microRNAs in
metastasis of non-small cell lung cancer. Front Biosci.
21:998–1005. 2016. View
Article : Google Scholar
|
|
20
|
Tie J and Fan D: Big roles of microRNAs in
tumorigenesis and tumor development. Histol Histopathol.
26:1353–1361. 2011.PubMed/NCBI
|
|
21
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang C, Zhang X, Wang HM, Liu XM, Zhang
XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an
oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis.
8:e27642017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang P, Wang X, Zhou Y and Hou Y:
Analysis of the correlation between the expression of miR-655 and
esophageal cancer prognosis. Oncol Lett. 13:4691–4694. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Zang W, Du Y, Ma Y, Li M, Li P,
Chen X, Wang T, Dong Z and Zhao G: Mir-655 up-regulation suppresses
cell invasion by targeting pituitary tumor-transforming gene-1 in
esophageal squamous cell carcinoma. J Transl Med. 11:3012013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin
X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by
regulating ADAM10 and β-catenin pathway in Hepatocellular
Carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv ZD, Kong B, Liu XP, Jin LY, Dong Q, Li
FN and Wang HB: miR-655 suppresses epithelial-to-mesenchymal
transition by targeting Prrx1 in triple-negative breast cancer. J
Cell Mol Med. 20:864–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Meng B, Wang Y and Li B: Suppression of
PAX6 promotes cell proliferation and inhibits apoptosis in human
retinoblastoma cells. Int J Mol Med. 34:399–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L, Li B, Zhang H, Bai S, Wang Y, Zhao B
and Jonas JB: Lentiviral vector-mediated PAX6 overexpression
promotes growth and inhibits apoptosis of human retinoblastoma
cells. Invest Ophthalmol Vis Sci. 52:8393–8400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai SW, Li B, Zhang H, Jonas JB, Zhao BW,
Shen L and Wang YC: Pax6 regulates proliferation and apoptosis of
human retinoblastoma cells. Invest Ophthalmol Vis Sci.
52:4560–4570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo J, Li H and Zhang C: MicroRNA-7
inhibits the malignant phenotypes of nonsmall cell lung cancer in
vitro by targeting Pax6. Mol Med Rep. 12:5443–5448. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Li Y, Liu Y, Xie P, Li F and Li G:
PAX6, a novel target of microRNA-7, promotes cellular proliferation
and invasion in human colorectal cancer cells. Dig Dis Sci.
59:598–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Zhang Y, Wang X and Zhao R:
microRNA-497 overexpression decreases proliferation, migration and
invasion of human retinoblastoma cells via targeting vascular
endothelial growth factor A. Oncol Lett. 13:5021–5027. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Zhu X, Zhu X, Wu Y, Liu Y, Yao B
and Huang Z: MiR-613 suppresses retinoblastoma cell proliferation,
invasion, and tumor formation by targeting E2F5. Tumour Biol.
39:10104283176916742017.PubMed/NCBI
|
|
37
|
Wei Y, Sun J and Li X: MicroRNA-215
enhances invasion and migration by targeting retinoblastoma tumor
suppressor gene 1 in high-grade glioma. Biotechnol Lett.
39:197–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao XQ, Liang B, Jiang K and Zhang HY:
Down-regulation of miR-655-3p predicts worse clinical outcome in
patients suffering from hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 21:748–752. 2017.PubMed/NCBI
|
|
39
|
Harazono Y, Muramatsu T, Endo H, Uzawa N,
Kawano T, Harada K, Inazawa J and Kozaki K: miR-655 is an
EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One.
8:e627572013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elso C, Lu X, Weisner PA, Thompson HL,
Skinner A, Carver E and Stubbs L: A reciprocal translocation
dissects roles of Pax6 alternative promoters and upstream
regulatory elements in the development of pancreas, brain, and eye.
Genesis. 51:630–646. 2013.PubMed/NCBI
|
|
41
|
Mascarenhas JB, Young KP, Littlejohn EL,
Yoo BK, Salgia R and Lang D: PAX6 is expressed in pancreatic cancer
and actively participates in cancer progression through activation
of the MET tyrosine kinase receptor gene. J Biol Chem.
284:27524–27532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xia X, Yin W, Zhang X, Yu X, Wang C, Xu S,
Feng W and Yang H: PAX6 overexpression is associated with the poor
prognosis of invasive ductal breast cancer. Oncol Lett.
10:1501–1506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao X, Yue W, Zhang L, Ma L, Jia W, Qian
Z, Zhang C and Wang Y: Downregulation of PAX6 by shRNA inhibits
proliferation and cell cycle progression of human non-small cell
lung cancer cell lines. PLoS One. 9:e857382014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li X, Yang L, Shuai T, Piao T and Wang R:
MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1
and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lim W and Song G: Inhibitory effects of
delphinidin on the proliferation of ovarian cancer cells via
PI3K/AKT and ERK 1/2 MAPK signal transduction. Oncol Lett.
14:810–818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jia S, Lu J, Qu T, Feng Y, Wang X, Liu C
and Ji J: MAGI1 inhibits migration and invasion via blocking
MAPK/ERK signaling pathway in gastric cancer. Chin J Cancer Res.
29:25–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
